Goal of Targeted Therapy for CLL

Targeted cancer therapies are designed to recognize a specific change in a cancer cell that drives the growth and spread of a tumor. These drugs zero in on their molecular or immunologic target. That's how they destroy or slow the growth of cancer cells. They do this without affecting most normal, healthy cells. Because most healthy tissues are spared, these treatments tend to cause fewer and less severe side effects than other standard treatments.

Monoclonal antibody therapy is a kind of targeted therapy. Recently this treatment has been developed for CLL. It precisely targets receptors on the outside of leukemia cells. The goal is to kill as many cancer cells as possible. It uses laboratory-created antibodies. They are similar to those your immune system makes naturally. They attach to cancer cells, killing them or blocking their growth. A monoclonal antibody used to treat CLL is called Campath (alemtuzumab). Rituxan (rituximab) is also commonly used but is not yet approved for this disease.


STAY CONNECTED

Copyright 2014 Main Line Health

Printed from: www.mainlinehealth.org/stw/Page.asp?PageID=STW016699

The information provided in this Web site is for informational purposes only. It is not a substitute for medical advice. All medical information presented should be discussed with your healthcare professional. See additional Terms of Use at www.mainlinehealth.org/terms. For more information, call 1.866.CALL.MLH.